# C_2011141EN.01001501.xml

| 12.5.2011 | EN | Official Journal of the European Union | C 141/15 |
| --- | --- | --- | --- |

12.5.2011

EN

Official Journal of the European Union

C 141/15

---

Prior notification of a concentration

(Case COMP/M.6162 — Pfizer/Ferrosan Consumer Healthcare Business)

(Text with EEA relevance)

2011/C 141/15

| 1. | On 2 May 2011 the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which Pfizer Inc. (‘Pfizer’, USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the consumer health care business of Ferrosan Holding A/S (‘Ferrosan’, Denmark) by way of purchase of shares. |
| --- | --- |

1.

On 2 May 2011 the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which Pfizer Inc. (‘Pfizer’, USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the consumer health care business of Ferrosan Holding A/S (‘Ferrosan’, Denmark) by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:






  — | for Pfizer: a publicly listed global research-based biomedical and pharmaceutical company active in discovering, developing, manufacturing, marketing and selling innovative medicines for humans and animals, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Pfizer: a publicly listed global research-based biomedical and pharmaceutical company active in discovering, developing, manufacturing, marketing and selling innovative medicines for humans and animals,

| — | for Ferrosan: the Consumer Healthcare business of Ferrosan Holding A/S. The Medical Devices business of Ferrosan is not subject of the proposed acquisition. |
| --- | --- |

—

for Ferrosan: the Consumer Healthcare business of Ferrosan Holding A/S. The Medical Devices business of Ferrosan is not subject of the proposed acquisition.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6162 — Pfizer/Ferrosan Consumer Healthcare Business, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6162 — Pfizer/Ferrosan Consumer Healthcare Business, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

1

---